One of Deepbridge Capital's Life Science EIS companies, Liverpool Chirochem Ltd., has announced the collaboration with Eurofins Discovery, a provider of products and services to the drug discovery industry.
This collaboration will provide enhanced chemical expertise by accessing Liverpool Chirochem's fragment library and PROTAC linker molecules to augment their integrated drug discovery platform, DiscoveryOne™.
Eurofins is one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing. With over 55,000 staff across a network of more than 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.
About Liverpool ChiroChem:
Liverpool ChiroChem is a chemical technology innovator, on a mission to accelerate NCE discovery and development through improved access to 3D chemical space. LCC was founded in 2014 and has operations in the UK and China, serving a global customer base within the life science sector.
Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).